E.g., 08/19/2019
E.g., 08/19/2019
Title Category Credit Event date Price
Advanced Practice Provider Core Curriculum: Screening Smarter for Prostate Cancer (2017)
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 Non-Physician Participation
$0.00 Member only benefit! Results of a recent survey sent to US based practicing urologists show that there has been an increase in the number of advanced practice providers (APPs) actively providing front-line urologic care. Based on these findings, it was determined that the AUA develop a modular curriculum to be used in advancing the standard of urologic education for APP’s.
Advanced Single and Multi-Port Robotic Urologic Oncology Masterclass (2019)
  • 14.00 AMA PRA Category 1 Credit™
  • 14.00 Non-Physician Participation
11/17/2019 $1,009.00 NEW for 2019: Simultaneous Live Surgeries and Interactive Case DiscussionDON'T DELAY AND REGISTER TODAY! (2018 course sold out!)
Androgen Axis Agents and Bone Target Therapies in Advanced Prostate Cancer: What's New Webcast (2018)
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Non-Physician Participation
$0.00 There is a growing need for urologists to be able to effectively manage castration-resistant prostate cancer (CRPC).  The AUA recently released its 2017 report on the educational needs of urologists in the area of CRPC. These findings show strong support for the AUA to influence key stakeholders in urology residency programs in order to increase the amount of exposure residents receive in this area.
AUA Annual Meeting Highlights (2018): Advanced and Castration-Resistant Prostate Cancer
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Non-Physician Participation
$0.00 There is a growing need for urologists to be able to effectively manage castration resistant prostate cancer (CRPC). CRPC is defined clinically as a failure of castration or androgen ablation therapy to prevent a worsening of a patient's prostate cancer and is associated with advanced disease. Approximately 28% of patients with prostate cancer will advance to CRPC. The median age at diagnosis of CRPC is 77 years and, as might be expected, these patients often have comorbidities, the most common of which are hypertension, dyspnea and anemia.
AUA Castration Resistant Prostate Cancer (CRPC) Guidelines and Therapeutic Advances in Metastatic Prostate Cancer Webcast 027IC (2019)
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
$0.00 This course will review the important and newly updated 2018 AUA Guidelines on Castration-Resistant Prostate Cancer. This includes a thorough discussion of new trials and approval of agents for MO non-metastatic nmCRPC. In addition, we will review therapeutic breakthroughs in the management of advanced and metastatic hormone naïve prostate cancer (mHSPPC). Faculty will highlight the management of patients with advanced prostate cancer, including mHSPC, nmCRPC, and CRPC, and how therapeutic options have been incorporated into evidence-based guidelines.
AUA2017 OnDemand Course Pass (2017) $299.00 Access some of the latest science from AUA2017 through the On-Demand Course Pass! The On-Demand Course Pass provides access to Webcasts of more than 90 instructional courses presented at AUA2017. Course topics span the spectrum of urologic medicine.
AUA2018 Abstracts and Posters (2018) $0.00 Member only benefit! This is a collection of abstracts presented at the AUA2018.This product does not provide CME.To access abstracts and posters, click REGISTER/TAKE COURSE tab. Then click ENROLL at the bottom of the page.
AUA2018 San Francisco Virtual Meeting (2018) $699.00 NEW for 2018: AUA2018 Virtual Meeting - Members Save $100!Access the latest science from the 2018 AUA Annual Meeting with the AUA2018 VIRTUAL MEETING.The Virtual Meeting provides online access to hundreds of scientific presentations from AUA2018, including:
Breaking Down the Barriers: Incorporating New IO Therapies Podcast Series - How to Properly Administer IO Therapies in an Infusion Suite (2018)
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Non-Physician Participation
$0.00 To improve clinicians’ understanding of current immunotherapeutic agents for the treatment of genitourinary (GU) cancer and to increase their ability to improve patient outcomes and the management of adverse events, the AUA is producing a series of online activities for clinicians and other healthcare professionals.The 2018 series is comprised of a variety of activities, including four live webinars, webcasts and podcasts plus three podcast addressing the barriers to immunotherapy treatment of GU cancer. All activities are complimentary.
Breaking Down the Barriers: Incorporating New IO Therapies Podcast Series - Managing Patient Side Effects (2018)
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Non-Physician Participation
$0.00 To improve clinicians’ understanding of current immunotherapeutic agents for the treatment of genitourinary (GU) cancer and to increase their ability to improve patient outcomes and the management of adverse events, the AUA is producing a series of online activities for clinicians and other healthcare professionals.The 2018 series is comprised of a variety of activities, including four live webinars, webcasts and podcasts plus three podcast addressing the barriers to immunotherapy treatment of GU cancer. All activities are complimentary.
Castration-Resistant Prostate Cancer (CRPC) Guideline Amendment Webcast (2018)
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Non-Physician Participation
$0.00 To encourage consistent, high quality, evidence-based treatment of patients with Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC), the AUA and Urology Care Foundation has produced a series of online activities and educational resources for healthcare professionals, patients and caregivers. One of those such activities is this complimentary AUA Castration-Resistant Prostate Cancer Guideline Amendment webcast.
Chemotherapy and Immunotherapy Options for Genitourinary Malignancies: A Primer for Urologists and Advanced Practice Providers Webcast 023IC (2019)
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
$0.00 Review of current chemotherapy and immunotherapy regimens for genitourinary malignancies, including bladder, renal, prostate, and testis cancers. Indications, outcomes, and toxicities will be discussed as well as clinical trial concepts. Survivorship issues will also be a focus of the session, which will include short, direct didactic lectures as well as a question and answer period. Standard of care chemotherapy regimens (eg MVAC for urothelial carcinoma) as well as newer immunotherapy options (eg checkpoint inhibition for renal cell carcinoma) will be included.
CPS Castration-Resistant Prostate Cancer Amendment (2018)
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
$0.00 Member only benefit! AUA Guidelines provide a comprehensive and rigorous summary of evidence relating to a variety of disease conditions, providing an indispensable resource for urologic education. The Clinical Problem Solving (CPS) Protocols guideline-based Case Scenarios were designed to help maximize the impact of the guidelines. The goal of this Guideline is  to provide a rational basis for treatment of patients with CRPC, based on currently available published data.
CPS Localized Prostate Cancer (2018)
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
$0.00 Member only benefit! AUA Guidelines provide a comprehensive and rigorous summary of evidence relating to a variety of disease conditions, providing an indispensable resource for urologic education. The Clinical Problem Solving (CPS) Protocols guideline-based Case Scenarios were designed to help maximize the impact of the guidelines. The purpose of this guideline is to provide a clinical framework for the diagnosis and treatment of clinically localized prostate cancer.
Emerging Treatment of M0 CRPC: Update on the AUA/SUO Guidelines and Beyond Webcast (2018)
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Non-Physician Participation
$0.00 There is a growing need for urologists to be able to effectively manage castration-resistant prostate cancer (CRPC).  The AUA recently released its 2017 report on the educational needs of urologists in the area of CRPC. These findings show strong support for the AUA to influence key stakeholders in urology residency programs in order to increase the amount of exposure residents receive in this area.

Pages